In Brief: Cardiac Pathways
This article was originally published in The Gray Sheet
Executive Summary
Cardiac Pathways: Arrhythmia Mapping System multiple-electrode catheter is used for the first time on a patient in The Netherlands. The system identified "three different sites responsible for ventricular tachycardias within 73 seconds, compared to three to four hours required by single-point mapping catheters," the company says. The 64-electrode basket catheter, used in conjunction with the company's Cooled Ablation radiofrequency catheter, is "introduced in a collapsed state...to enable its traverse through the arteries" to the left ventricle, where it is "fully deployed" using eight "arms" to map the entire ventricle "within several heartbeats." Cardiac Pathways submitted an investigational device exemption application for the system to FDA in September...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.